Acta Biomater:多层膜涂覆的钛植体可有效促进骨生成和血管生成

2018-05-19 MedSci MedSci原创

本研究中,研究人员使用壳聚糖-儿茶酚(Chi-C)、明胶(凝胶)和羟基磷灰石(HA)纳米纤维组成的多层结构的表面改性的钛(Ti)基底,探究骨愈合过程中骨形成和血管生成的相互作用。 采用Transwell共培养,创面愈合实验,酶联免疫吸附实验(ELISA),定量实时聚合酶链反应(qRT-PCR),免疫印迹和免疫组织化学染色技术评估不同Ti底物上生长的脂肪来源的间充质干细胞(Ad-MSCs)和人

本研究中,研究人员使用壳聚糖-儿茶酚(Chi-C)、明胶(凝胶)和羟基磷灰石(HA)纳米纤维组成的多层结构的表面改性的钛(Ti)基底,探究骨愈合过程中骨形成和血管生成的相互作用。

采用Transwell共培养,创面愈合实验,酶联免疫吸附实验(ELISA),定量实时聚合酶链反应(qRT-PCR),免疫印迹和免疫组织化学染色技术评估不同Ti底物上生长的脂肪来源的间充质干细胞(Ad-MSCs)和人脐静脉内皮细胞(HUVECs)的粘附、形态和迁移。

研究了底物对Ad-MSCs的成骨分化的影响,以及Ad-MSCs与HUVECs的相互旁分泌影响。结果显示,多层Ti底物直接调节Ad-MSCs和血管生成HUVECs的细胞功能,并通过体外细胞- 基质相互作用增强旁分泌作用介导细胞间的通讯。体内实验结果表明,表面改性钛种植体诱导的微环境变化促进了骨髓间充质干细胞的粘附、募集和增殖,促进了骨愈合中的成骨和血管生成。

综上所述,该研究结果表明,多层膜涂覆的Ti底物在体外正向介导细胞生物学功能并改善体内骨愈合。

原始出处:

Chen W, Xu K, et al., Multilayered coating of titanium implants promotes coupled osteogenesis and angiogenesis in vitro and in vivo. Acta Biomater. 2018 Apr 25. pii: S1742-7061(18)30246-0. doi: 10.1016/j.actbio.2018.04.043.

评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1918104, encodeId=18d0191810460, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Jun 18 18:09:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849601, encodeId=ed561849601f0, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Jan 09 11:09:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679704, encodeId=bc2c16e9704fb, content=<a href='/topic/show?id=d4ac9639efa' target=_blank style='color:#2F92EE;'>#钛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96397, encryptionId=d4ac9639efa, topicName=钛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927227807332, createdName=30397613, createdTime=Wed Aug 08 21:09:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316690, encodeId=470f31669042, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:24:44 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316689, encodeId=0108316689fa, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:22:00 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-06-18 智慧医人
  2. [GetPortalCommentsPageByObjectIdResponse(id=1918104, encodeId=18d0191810460, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Jun 18 18:09:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849601, encodeId=ed561849601f0, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Jan 09 11:09:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679704, encodeId=bc2c16e9704fb, content=<a href='/topic/show?id=d4ac9639efa' target=_blank style='color:#2F92EE;'>#钛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96397, encryptionId=d4ac9639efa, topicName=钛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927227807332, createdName=30397613, createdTime=Wed Aug 08 21:09:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316690, encodeId=470f31669042, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:24:44 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316689, encodeId=0108316689fa, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:22:00 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2019-01-09 windight
  3. [GetPortalCommentsPageByObjectIdResponse(id=1918104, encodeId=18d0191810460, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Jun 18 18:09:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849601, encodeId=ed561849601f0, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Jan 09 11:09:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679704, encodeId=bc2c16e9704fb, content=<a href='/topic/show?id=d4ac9639efa' target=_blank style='color:#2F92EE;'>#钛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96397, encryptionId=d4ac9639efa, topicName=钛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927227807332, createdName=30397613, createdTime=Wed Aug 08 21:09:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316690, encodeId=470f31669042, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:24:44 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316689, encodeId=0108316689fa, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:22:00 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-08-08 30397613
  4. [GetPortalCommentsPageByObjectIdResponse(id=1918104, encodeId=18d0191810460, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Jun 18 18:09:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849601, encodeId=ed561849601f0, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Jan 09 11:09:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679704, encodeId=bc2c16e9704fb, content=<a href='/topic/show?id=d4ac9639efa' target=_blank style='color:#2F92EE;'>#钛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96397, encryptionId=d4ac9639efa, topicName=钛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927227807332, createdName=30397613, createdTime=Wed Aug 08 21:09:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316690, encodeId=470f31669042, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:24:44 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316689, encodeId=0108316689fa, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:22:00 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-05-19 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1918104, encodeId=18d0191810460, content=<a href='/topic/show?id=4f26341994' target=_blank style='color:#2F92EE;'>#Bio#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3419, encryptionId=4f26341994, topicName=Bio)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智慧医人, createdTime=Mon Jun 18 18:09:00 CST 2018, time=2018-06-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849601, encodeId=ed561849601f0, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Wed Jan 09 11:09:00 CST 2019, time=2019-01-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1679704, encodeId=bc2c16e9704fb, content=<a href='/topic/show?id=d4ac9639efa' target=_blank style='color:#2F92EE;'>#钛#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=112, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=96397, encryptionId=d4ac9639efa, topicName=钛)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=927227807332, createdName=30397613, createdTime=Wed Aug 08 21:09:00 CST 2018, time=2018-08-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316690, encodeId=470f31669042, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=124, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:24:44 CST 2018, time=2018-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=316689, encodeId=0108316689fa, content=学习了.谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=105, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Sat May 19 21:22:00 CST 2018, time=2018-05-19, status=1, ipAttribution=)]
    2018-05-19 1209e435m98(暂无昵称)

    学习了.谢谢分享

    0

相关资讯

骨巨细胞瘤1例

患者,男,30岁

骨纤维异样增殖症1例

35岁男性患者,确诊股骨近端纤维异样增殖症。幸亏患者就诊及时,如果出现股骨颈病理性骨折再来诊疗,不仅增加手术难度,还大大增加术后股骨头坏死的发生率。患者正值青壮年,如何选择恰当的治疗方案?

Radiology:每一次强化,都会有对比剂存留在你的体内

本研究旨在对非侵入测量系统评价骨中钆剂沉积情况并探究钆剂对比剂增强与骨中钆剂沉积的关系,研究人员将结果发表在Radiology上。

Adv Sci:基于石墨烯的miRNA转染可阻断前粘连蛋白融合增加骨形成和血管形成

本研究旨在设计一种石墨烯基miRNA转染药物递送系统用于抗吸收治疗。使用负载有miR-7b过表达质粒的聚乙烯亚胺(PEI)功能化的氧化石墨烯(GO)复合物开发了高效的非病毒基因递送系统。GO-PEI复合物在可接受的细胞毒性范围内表现出优异的转染效率。GO-PEI-miR-7b转染后miR-7b的过表达通过阻碍基本促融合分子树突细胞特异性跨膜蛋白的表达明显消除破骨细胞(OC)融合和骨吸收活性。然而,

骨巨细胞瘤恶变1例

骨巨细胞瘤是较常见的良性骨肿瘤,通常不难得出诊断,但复发可能性较大。面对发生几率很低的骨巨细胞瘤恶变,治疗方法主要是什么?重建方法通常采用什么?行预防性内固定,能否仍考虑行骨水泥填充?

周围型骨发育障碍1例

患者,男,8岁